Human Tripeptidyl-Peptidase I/TPP1 Antibody

Name: Human Tripeptidyl-Peptidase I/TPP1 Antibody
Brand: R&D Systems
SKU: MAB2237
Rating: 4 (1 reviews)

Catalog #: MAB2237
1 Citation 1 Review Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB2237-SP
MAB2237-100
MAB2237-500

All Tripeptidyl-Peptidase I/TPP1 Antibodies

Product Details

Citations (1)

FAQs

Supplemental Products

Reviews (1)

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Tripeptidyl-Peptidase I/TPP1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human Tripeptidyl‑Peptidase I/TPP1 in direct ELISAs and Western blots.

Source

Monoclonal Mouse IgG_2A Clone # 254008

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Tripeptidyl‑Peptidase I/TPP1
Ser20-Pro563
Accession # O14773

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human Tripeptidyl-Peptidase I/CLN2

Immunoprecipitation

25 µg/mL

Conditioned cell culture medium spiked with Recombinant Human Tripeptidyl-Peptidase I/TPP1, see our available Western blot detection antibodies

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Tripeptidyl-Peptidase I/TPP1

Tripeptidyl-Peptidase I (TPP1), also known as tripeptidyl aminopeptidase, is a lysosomal peptidase which can hydrolyze tripeptides from the N-termini of oligopeptides and also possesses weak endopeptidase activity (1‑3). TPP1 is a serine peptidase with a Ser-Glu-Asp catalytic triad, making it a member of the sedolisin family (4). The TPP1 precursor undergoes autoactivation under conditions of acidic pH (4). TPP1 is expressed in many tissues, with elevated expression in tissues associated with peptide hormone production (5). Mutations in TPP1 have been shown to be a cause of classic late‑infantile neuronal ceroid lipofuscinosis (CLN2), a lysosomal storage disease (6).

References

Sleat, D.E. et al. (1997) Science 277:1802.
Ezaki, J. et al. (1999) J. Neurochem. 72:2573.
Tomkinson, B. (1999) Trends Biochem. Sci. 24:355.
Lin, L. et al. (2001) J. Biol. Chem. 276:2249.
Kida, E. et al. (2001) J. Neuropathol. Exp. Neurol. 60:280.
Sleat, D.E. et al. (1999) Am. J. Hum. Genet. 64:1511.

Entrez Gene IDs

1200 (Human)

Alternate Names

Cell growth-inhibiting gene 1 protein; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); CLN2; CLN2EC 3.4.14.9; growth-inhibiting protein 1; LINCL; LPIC; lysosomal pepstatin insensitive protease; Lysosomal pepstatin-insensitive protease; MGC21297; TPP1; TPP-1; TPP-I; Tripeptidyl aminopeptidase; tripeptidyl peptidase I; tripeptidyl-peptidase 1; TripeptidylPeptidase I; Tripeptidyl-Peptidase I

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Serine Proteases and Regulators

Citation for Human Tripeptidyl-Peptidase I/TPP1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

Characterization of AAV-mediated dorsal root ganglionopathy
Authors: Nicholas Buss, Lisa Lanigan, Jillynne Zeller, Derek Cissell, Monica Metea, Eric Adams et al.
Molecular Therapy - Methods & Clinical Development